Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martinelli, G
Right arrow Articles by Baccarani, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martinelli, G
Right arrow Articles by Baccarani, M
Haematologica, Vol 89, Issue 4, 495-497
Copyright © 2004 by Ferrata Storti Foundation

Letter

Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely

G Martinelli, M Rondoni, S Buonamici, E Ottaviani, PP Piccaluga, M Malagola, and M Baccarani

Many patients with the inv(16) positive acute myeloid leukemia (AML) achieve complete remission (CR). Using real-time reverse transcriptase polymerase chain reaction (RT-PCR), we previously proposed critical CBFbeta-MYH11 transcript copy number thresholds to predict relapse or cure. We now update the molecular follow-up of our patients, also presenting the therapeutic management of these patients.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.